Takeda Says FDA Grants Priority Review Of Maribavir For Treatment Of CMV Infection - Quick Facts

Takeda Pharmaceutical Company Limited (TAK) announced that the U.S. FDA has accepted a New Drug Application for maribavir for the treatment of CMV infection in those that are refractory with or without resistance, in solid organ transplant or hematopoietic cell transplant recipients.

Takeda noted that its NDA is based on Phase 3 Trial of Maribavir which met its primary endpoint of superiority compared to conventional antiviral therapies in transplant recipients with R/R CMV infection.

Maribavir has been granted Orphan Drug Designation for treatment of clinically significant CMV viremia and disease in at-risk patients and also Breakthrough Therapy Designation as a treatment for CMV infection and disease in transplant patients resistant or refractory to prior therapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
After Disney World, retail giant Walmart Inc. (WMT) makes it mandatory for all its employees to wear mask on their facilities in the "high-risk" states where the Delta variant of Coronavirus has become menacing. The orders will be in effect immediately. The Center for Disease Control and Prevention... Generac Power Systems is recalling 325,735 units of Generac and DR 6500 Watt and 8000 Watt portable generators for potential risk of finger amputation and crushing hazards, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. These include 4,575 units sold in Canada. Omaha, Nebraska- based Greater Omaha Packing is recalling around 295,236 pounds of raw beef products citing the possible presence of E. coli O157:H7, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The raw beef products intended for non-intact use were produced on July 13.
Follow RTT